Burning Rock Biotech Limited BNR
Annual
Quarterly
FY2025 · ended Dec 31, 2025 · Revenue $77.16M, +9.2% YoY · Filed Apr 28, 2026
Burning Rock Biotech Limited (BNR) files with the SEC under industry code 8071, Services-Medical Laboratories. In fiscal 2025, which ended Dec 31, 2025, it reported revenue of $77.2 million and a net loss of $7.9 million. Free cash flow was -$4.8 million. As of Dec 31, 2025 it held $68.4 million in cash and investments and $6.1 million in total debt.
Revenue
$77.16M
+9.2% vs prior year
Net income
$-7.92M
+83.3% vs prior year
Operating cash flow
$-4.07M
+67.8% vs prior year
Free cash flow
$-4.82M
+64.0% vs prior year
EPS
—
Dividend per share
None
Shares outstanding
0
Net cash
$62.27M
FY 2025
Operating margin
-10.2%
FY 2025
Company profile
- Industry
- Services-Medical Laboratories (SIC 8071)
- Listed as
- BNR (Nasdaq)
- Headquarters
- Guangzhou, Guangdong
- SEC filer status
- Non-accelerated filer
- SEC CIK
- 1792267
Other Services-Medical Laboratories companies
- Natera, Inc. NTRA
- Labcorp Holdings Inc. LH
- Quest Diagnostics Inc DGX
- Guardant Health, Inc. GH
- Caris Life Sciences, Inc. CAI
- GRAIL, Inc. GRAL
- RadNet, Inc. RDNT
- BillionToOne, Inc. BLLN
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $77.2M | $70.7M | $75.7M | $81.7M | $79.7M |
| Operating income | -$7.8M | -$49.0M | -$94.3M | -$142.1M | -$125.1M |
| Net income | -$7.9M | -$47.5M | -$92.1M | -$140.8M | -$125.0M |
| Operating cash flow | -$4.1M | -$12.6M | -$36.0M | -$66.2M | -$75.0M |
| Free cash flow | -$4.8M | -$13.4M | -$37.2M | -$75.2M | -$107.1M |
| Total assets | $117.3M | $121.3M | $146.5M | $230.2M | $357.6M |
| Total liabilities | $40.8M | $41.7M | $38.3M | $62.2M | $68.0M |
| Stockholders' equity | $76.5M | $79.6M | $108.2M | $167.9M | $289.6M |
| Cash and investments | $68.4M | $71.2M | $86.6M | $131.3M | $234.6M |
| Total debt | $6.1M | $7.2M | $1.7M | $7.4M | $13.6M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 6-K | Current report (foreign issuer) | Sep 10, 2026 | Sep 10, 2026 |
| 6-K | Current report (foreign issuer) | Jun 9, 2026 | Jun 9, 2026 |
| 20-F | Annual report (foreign issuer) | Apr 28, 2026 | Dec 31, 2025 |
| 6-K | Current report (foreign issuer) | Mar 13, 2026 | Mar 12, 2026 |
| 6-K | Current report (foreign issuer) | Dec 23, 2025 | Dec 23, 2025 |
| 6-K | Current report (foreign issuer) | Dec 1, 2025 | Dec 1, 2025 |
All 169 Burning Rock Biotech Limited SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.